Etanercept therapy in patients with a positive tuberculin skin test

Clinical and Experimental Rheumatology

Volumn 25, Issue 5, 2007, Pages 743-745

  Manadan, Augustine M ^a,b,c   Joyce, Kevin ^b   Sequeira, Winston ^a   Block, Joel A ^b  

^a Jr Hospital of Cook County   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c Section of Rheumatology   (United States)

Author keywords

Etanercept; PPD; Rheumatoid arthritis; Tuberculosis; Tumor necrosis factor

Indexed keywords

ETANERCEPT; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GRANULOMATOSIS; HUMAN; MALE; MEDICAL RECORD REVIEW; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THORAX RADIOGRAPHY; TUBERCULIN TEST; TUBERCULOSIS;

ANTIRHEUMATIC AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; MALE; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; RHEUMATIC DISEASES; RISK FACTORS; TUBERCULIN TEST; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 37349096305     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. MORELAND LW, SCHIFF AH, BAUMGARTNER SW: Etanercept therapy in RA: a randomized controlled trial. Ann Intern Med 1999; 130: 478.
2. FLYNN JL, GOLDSTEIN MM, CHAN J et al.: Tumor Necrosis Factor-TNF-α is required in the protective immune response against Mycobacterial tuberculosis in mice. Immunity 1995; 2: 561-72
3. KEAN J, GERSHON S, WISE RP et al.: Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. NEJM 2001; 345: 1098-104.
4. MOHAN AK, COTÉ TR, BLOCK JA, MANADAN AM, SIEGEL JN, BRAUN MB: Tuberculosis Following the Use of Etanercept a Tumor Necrosis Factor Inhibitor. Clin Infect Dis 2004; 39: 295-9.
5. MANADAN AM, MOHAN AK, COTÉ TR, SIEGEL JN, SEQUEIRA W, BLOCK JA: Tuberculosis and Etanercept Therapy. Arthritis Rheum 2002; 46 (Suppl.): Ab.356: S166.
6. GÓMEZ-REINO JJ, CARMONA L, VALVERDE VR, MOLA EM, MONTERO MD: Treatment of Rheumatoid Arthritis with Tumor Necrosis Factor Inhibitors May Predispose to Significant Increase in Tuberculosis Risk. Arthritis Rheum 2003; 48: 2122-7.
7. WOLFE F, MICHAUD K, ANDERSON J, URBANSKY K: Tuberculosis Infection in Patients with Rheumatoid Arthritis and the Effect of Infliximab Therapy. Arthritis Rheum 50: 372-9
8. HORSBURGH CR: Priorities for the Treatment of Latent Tuberculosis Infection in the United States. NEJM 2004; 350: 2060-6
9. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161: S221.
10. COMSTOCK GW, BAUM C, SNIDER DF: Isoniazid prophylaxis among Alaskan Eskimos final report of the Bethel isoniazid studies. Am Rev Respir Dis 1979; 119: 827.
11. ELLERIN T, RUBIN RH, WEINBLATT ME: Infections and Anti-Tumor Necrosis Factor α Therapy. Arthritis Rheum 2003; 48: 3013-22.
12. GARDAM MA, KEYSTONE EC, MENZIES R et al.: Anti-tumour necrosis factor agents and tuberculosis risk: Management of action and clinical management. The Lancet Infectious Disease 2003; 3: 148-55.
13. KEANE J: Tumor Necrosis Factor Blockers and Reactivation of Latent Tuberculosis. Clinical Infectious Disease 2004; 39: 300-2.
14. BIEBER J, KAVANAUGH A: Tuberculosis and opportunistic infections: Relevance to biologic agents. Clin Exp Rheumatol 2004; 22: S126-33.
15. CDC: Tuberculosis Associated with Blocking Agents Against Tumor Necrosis Factor-Alpha - California. MMWR 2004; 53: 683-6.
16. CDC: Trends in Tuberculosis - United States. MMWR 2005; 54: 245-9.
17. CARMONA L, GÓMEZ-REINO JJ, RODRÍGUEZ-VALVERDE V et al.: Effectiveness of Recommendations to Prevent Reactivation of Latent Tuberculosis Infection in Patients Treated With Tumor Necrosis Factor Antagonists. Arthritis Rheum 2005; 52: 1766-72.